Cargando…

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

BACKGROUND: Chk1 inhibitors are currently in clinical trials as putative potentiators of cytotoxic chemotherapy drugs. Chk1 inhibitors may exhibit single agent anti-tumor activity in cancers with underlying DNA repair, DNA damage response or DNA replication defects. METHODS: Here we describe the cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bryant, Christopher, Rawlinson, Rebecca, Massey, Andrew J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137066/ https://www.ncbi.nlm.nih.gov/pubmed/25104095 http://dx.doi.org/10.1186/1471-2407-14-570

Ejemplares similares

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
por: Rawlinson, Rebecca, et al.
Publicado: (2014)

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2020)

Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
por: Bryant, Christopher, et al.
Publicado: (2014)

Chk1 inhibition as a novel therapeutic strategy in melanoma
por: Hwang, Bor-Jang, et al.
Publicado: (2018)

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy
por: Stefanski, Casey D., et al.
Publicado: (2022)

The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy
por: Zhou, Zhi-rui, et al.
Publicado: (2017)

Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer
por: Lim, Sera, et al.
Publicado: (2020)

Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Jin, Juan, et al.
Publicado: (2018)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation
por: Choi, Changhoon, et al.
Publicado: (2020)

Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
por: Wang, Edina, et al.
Publicado: (2018)

Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
por: Chalakur-Ramireddy, Naveen K.R., et al.
Publicado: (2018)

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
por: Medina, Mauricio A., et al.
Publicado: (2020)

EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Wang, Chao-Qun, et al.
Publicado: (2017)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase
por: Wayne, Joanne, et al.
Publicado: (2016)

Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer
por: Kung, Che-Pei, et al.
Publicado: (2020)

Disintegrin-like Protein Strategy to Inhibit Aggressive Triple-Negative Breast Cancer
por: Limam, Inès, et al.
Publicado: (2023)

Novel strategies to target chemoresistant triple-negative breast cancer
por: Venkatesh, Jaganathan, et al.
Publicado: (2020)

Modification of tumour cell metabolism modulates sensitivity to Chk1 inhibitor-induced DNA damage
por: Massey, Andrew J.
Publicado: (2017)

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
por: Li, Mengxing, et al.
Publicado: (2021)

Revealing targeted therapeutic opportunities in triple-negative breast cancers: A new strategy
por: Poage, Graham M, et al.
Publicado: (2013)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
por: Li, Shuanghe, et al.
Publicado: (2022)

Multi-Level Control of the ATM/ATR-CHK1 Axis by the Transcription Factor E4F1 in Triple-Negative Breast Cancer
por: Batnini, Kalil, et al.
Publicado: (2022)

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
por: Li, Ching-Chia, et al.
Publicado: (2015)

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
por: Bennett, Christina N, et al.
Publicado: (2012)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
por: Johnson, Rebecca, et al.
Publicado: (2013)

Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
por: Chan, Jack J., et al.
Publicado: (2019)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells
por: Lee, Sol, et al.
Publicado: (2022)

Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Therapeutic landscape in mutational triple negative breast cancer
por: Shi, Yaqin, et al.
Publicado: (2018)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer
por: Kim, Hyo-Jin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a796v2llndtjsu2ok9ndtuab15